Chinese Journal of Cancer Research

Papers
(The TQCC of Chinese Journal of Cancer Research is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas58
Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial49
Gastric cancer surgery in South Korea: Past, present, and future34
Efficacy of ctDNA methylation combined with traditional detection modality to detect liver cancer among high-risk patients: A multicenter diagnostic trial34
Transforming cancer cells for long-term living with cancer: An inspiring new approach33
Pathogenic germline variants in mismatch repair genes in patients with microsatellite instability-high gastric cancer32
Focal ablation therapy presents promising results for selectively localized prostate cancer patients30
Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics29
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis28
National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)23
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives23
Mn-based cGAS-STING activation for tumor therapy23
Detection and classification of breast lesions using multiple information on contrast-enhanced mammography by a multiprocess deep-learning system: A multicenter study23
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors22
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A20
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery: Final results of a phase II trial15
Health economic evaluation on population-based Helicobacter pylori eradication and endoscopic screening for gastric cancer prevention14
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma14
New roles of tumor-derived exosomes in tumor microenvironment14
Optimal response population after neoadjuvant therapy for patients with locally advanced gastric cancer: A multicenter study14
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China14
Hypoxic tumor microenvironment: Destroyer of natural killer cell function14
Burden of liver cancer: From epidemiology to prevention12
Corrigendum to Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)12
Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study12
Genomic characterization of peritoneal lavage cytology-positive gastric cancer11
Pan-cancer tumor-infiltrating T cells: A great hallmark in cancer immunology research11
Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs. capecitabine for pathological stage N2 rectal cancer11
Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: A nationwide multicenter cross-sectional study10
Research progress of minimally invasive surgery for gastric cancer10
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors10
Lung cancer burden and trends from 2000 to 2018 in China: Comparison between China and the United State10
Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer9
Comments on National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)9
Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors9
Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians’ acceptance of practice-changing data8
Advances, breakthroughs, and challenges in gastric cancer surgery7
SOX11 as a potential prognostic biomarker in hepatocellular carcinoma linked to immune infiltration and ferroptosis7
Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies6
Variant rs8400 enhances ALKBH5 expression through disrupting miR-186 binding and promotes neuroblastoma progression6
Clinicopathological and molecular features of HR+/HER2− breast cancer patients with distinct endocrine resistance patterns6
Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers5
Laparoscopic vs. open lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction: An exploratory, observational, prospective, IDEAL stage 2b cohort study (CLA5
Distal margin distance in radical resection of locally advanced rectal cancer after neoadjuvant therapy5
Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in 5
Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment5
Postoperative functional evaluation of gastrectomy for gastric cancer5
Inducing immunogenic cell death in immuno-oncological therapies5
0.055188894271851